Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome
6/22/2012 10:18:13 AM
OSAKA, Japan & BEDMINSTER, N.J.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP, “NPS”), jointly announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product teduglutide (tradename in Europe: Revestive®) as a once-daily treatment for adult patients with short bowel syndrome (SBS). The marketing authorization application was submitted in March 2011.
comments powered by